siltuximab

Home
Ligands
siltuximab

GtoPdb Ligand ID: 7396

Synonyms: cLLB8 | CNTO 328 | Sylvant®

siltuximab is an approved drug (EMA & FDA (2014))

Comment: Siltuximab is a monoclonal antibody targeting interleukin 6 (IL-6) [6].
Peptide sequences for the heavy and light chains of this antibody are annotated in its IMGT/mAb-DB record. The invention of siltuximab is claimed in patent US7291721 [2].

References
1. Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, Riveros C, Davidson M, Graña C, Bonnet H et al.. (2023) Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev, 6 (6): CD013881. [PMID:37260086]
2. Giles-Komar J, Knight D, Peritt D, Trikha M. (2007) Anti-IL-6 antibodies, compositions, methods and uses. Patent number: US7291721. Assignee: Centocor, Inc.. Priority date: 14/11/2001. Publication date: 06/11/2007.
3. Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, Bancos A, Tigu B, Rotariu P, Urian L et al.. (2024) Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience. J Hematol, 13 (5): 207-215. [PMID:39493599]
4. Lang E, van Rhee F. (2024) Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances. Blood Rev, 64: 101161. [PMID:38087716]
5. Panda AK, Padhi S, Pati A, Nayak TKS. (2021) Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted. Hum Cell, 34 (6): 1943-1944. [PMID:34524645]
6. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al.. (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol, 28 (23): 3701-8. [PMID:20625121]
7. Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C. (2022) A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab. Adv Ther, 39 (3): 1126-1148. [PMID:35072887]
8. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al.. (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood, 74 (4): 1360-7. [PMID:2788466]

References

1. Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, Riveros C, Davidson M, Graña C, Bonnet H et al.. (2023)
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Cochrane Database Syst Rev, 6 (6): CD013881. [PMID:37260086]

2. Giles-Komar J, Knight D, Peritt D, Trikha M. (2007)
Anti-IL-6 antibodies, compositions, methods and uses.
Patent number: US7291721. Assignee: Centocor, Inc.. Priority date: 14/11/2001. Publication date: 06/11/2007.

3. Jitaru C, Symeonidis A, Badelita S, Katodritou E, Colita A, Mpanti A, Bancos A, Tigu B, Rotariu P, Urian L et al.. (2024)
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience.
J Hematol, 13 (5): 207-215. [PMID:39493599]

4. Lang E, van Rhee F. (2024)
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
Blood Rev, 64: 101161. [PMID:38087716]

5. Panda AK, Padhi S, Pati A, Nayak TKS. (2021)
Efficacy of IL-6 antagonists in the treatment of COVID-19 patients: further randomized controlled trials are warranted.
Hum Cell, 34 (6): 1943-1944. [PMID:34524645]

6. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M et al.. (2010)
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
J Clin Oncol, 28 (23): 3701-8. [PMID:20625121]

7. Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C. (2022)
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.
Adv Ther, 39 (3): 1126-1148. [PMID:35072887]

8. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T et al.. (1989)
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.
Blood, 74 (4): 1360-7. [PMID:2788466]